← Back to screener

Denali Therapeutics Inc. DNLI

Rank #2087 · Nasdaq · $3.0B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
34.3
P/E
-20.7
P/B
2.88
ROE
-13.9%
Op. Margin
-59.5%
Debt Ratio
14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -20.7x, P/B 2.88x. Ranks in the top 64% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -13.9%. Ranks in the top 83% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 14%. Ranks in the top 11% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 204.7% year over year. Ranks in the top 2% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018$0.0B$-0.1B$-0.1B$-0.0B–-134
2019$0.0B$-0.1B$-0.1B$-0.1B–-122
2020$0.1B$-0.0B$-0.0B$0.5B-35.934
2021$0.0B$-0.2B$-0.2B$0.5B-799.183
2022$0.3B$0.1B$0.1B$0.4B18.7112
2023$0.0B$-0.3B$-0.3B$1.2B-607.836
2024$0.1B$-0.3B$-0.3B$1.0B-314.213
2025$0.3B$-0.2B$-0.1B$1.0B-59.514

← See the full screener